PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nogapendekin Alfa Inbakicept→

Nogapendekin Alfa Inbakicept PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Interleukin-15 superagonist complexIL-15 receptor agonist immunotherapy
Mechanism of action
A recombinant IL-15 superagonist complex that activates IL-15 receptor signalling on natural killer cells and CD8-positive T cells, promoting their proliferation, activation and antitumour immune responses within the bladder.
Indications / reported uses
  • In combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours, under the US ANKTIVA indication; for intravesical use only

Sources: US DailyMed — ANKTIVA (nogapendekin alfa inbakicept) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Nogapendekin Alfa Inbakicept PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nogapendekin Alfa Inbakicept Permitted Daily Exposure (PDE) report (the Nogapendekin Alfa Inbakicept PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nogapendekin Alfa Inbakicept Occupational Exposure Limit (OEL) report (the Nogapendekin Alfa Inbakicept OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.